Hostname: page-component-7c8c6479df-hgkh8 Total loading time: 0 Render date: 2024-03-28T21:43:32.013Z Has data issue: false hasContentIssue false

Clinical trials of drug and behaviour therapies: methodological issues

Published online by Cambridge University Press:  02 January 2018

Partha Sarathi Biswas
Affiliation:
Department of Psychiatry, Ranchi Institute of Neuro-Psychiatry and Allied Sciences (RINPAS), Kanke, Ranchi, India. Email: drparthas@rocketmail.com
Devosri Sen
Affiliation:
Department of Clinical Psychology, Central Institute of Psychiatry (CIP), Kanke, Ranchi, India
V. K. Sinha
Affiliation:
Central Institute of Psychiatry (CIP), Ranchi, India
Rights & Permissions [Opens in a new window]

Abstract

Type
Columns
Copyright
Copyright © Royal College of Psychiatrists, 2011 

Shimazu et al Reference Shimazu, Shimodera, Mino, Nishida, Kamimura and Sawada1 designed a randomised controlled trial highlighting the efficacy of family psychoeducation compared with treatment as usual in the maintenance treatment of major depression. By definition, the index trial was a pragmatic trial. The authors did not use behavioural ‘placebo’ control groups, although in such a trial they are not necessarily needed. However, this study has faced bias with regard to recruitment and selection procedures, such as the exclusion of previous non-responders. Sample homogeneity is one of the ways to enhance the power of the study. The authors excluded patients who received electroconvulsive therapy, which improved the homogeneity. The bipolarity status, number of previous episodes, duration of untreated psychosis (DUP) and associated specifier (e.g. melancholic, atypical and psychotic features) might have been taken as inclusion criteria to improve it further. Alternatively, as clinical relevance is the primary consideration in pragmatic trials, differences in treatment structure (e.g. number of antidepressants, doses and length of treatment/ follow-up sessions) may be ignored if they reflect clinical practice.

Participants might have a preference for only antidepressant or combined therapy, and this preference might undermine adherence (which is not addressed in this study), influence drop-out rate, and even affect treatment response. Reference Elkin, Pilkonis, Docherty and Sotsky2 This could be avoided with a two-level randomisation design: first, randomised to two different treatment protocols; and second, randomised to receive preferred treatment. The participants’ expectation, which might be a confounding factor, was not a concern in this trial.

The frequently raised question ‘Does combining family psychoeducation therapy with antidepressant treatment enhance the maintenance of treatment effects following drug withdrawal?’ can only be addressed following drug withdrawal. Reference Holroyd, Tolison and Kunkel3

Allegiance effects could have been minimised if the drug and family psychoeducation were each administered by professionals who did not have primary allegiance to the type of therapy they were administering and expertise in its administration. This issue is not addressed clearly by Shimazu et al. Reference Shimazu, Shimodera, Mino, Nishida, Kamimura and Sawada1

In this pragmatic trial, the goal was to duplicate clinical practice, including practitioners’ clinical judgements in tailoring treatments to patients. However, therapy protocols need to be clearly specified (especially whether receiving antidepressant or antipsychotic drugs) and fidelity to treatment protocols maintained if a clearly defined therapy is to be evaluated and the therapy is to be duplicated by others. Information obtained from this drug–behaviour therapy trial might be maximised if measures of the putative therapeutic mechanisms of behavioural treatment (e.g. self-efficacy, symptoms-related coping) were obtained.

Adherence data can provide useful information about treatment acceptability in pragmatic trials. Adherence appears to be more easily assessed with drug therapy. Measures of adherence with behaviour therapy are often limited to self-report, although completion of in-therapy tasks and/or homework assignments and tape recorders capable of monitoring the use of relaxation tapes have been used as ‘objective’ measures of adherence. Reference Epstein4 Had the authors taken some of these measures, the confounding due to adherence would have been reduced.

The authors could have entered some additional factors into the Cox proportional hazards analysis, such as adherence, DUP, type of antidepressant, predominant side-effect and psychotic status of current episode, which may have made the analysis better powered.

The methodological issues we discuss here are not considered immutable, but are expected to evolve as investigators creatively tackle design issues when conducting drug–behaviour trials.

References

1 Shimazu, K, Shimodera, S, Mino, Y, Nishida, A, Kamimura, N, Sawada, K, et al. Family psychoeducation for major depression: randomised controlled trial. Br J Psychiatry 2011; 198: 385–90.CrossRefGoogle ScholarPubMed
2 Elkin, I, Pilkonis, PA, Docherty, JP, Sotsky, SM. Conceptual and methodological issues in comparative studies of psychotherapy and pharmacotherapy. I. Active ingredients and mechanisms of change. Am J Psychiatry 1988; 145: 909–17.Google ScholarPubMed
3 Holroyd, K. Integrating pharmacologic and nonpharmacologic treatments. In Headache Diagnosis and Interdisciplinary Treatment (eds Tolison, CD, Kunkel, RS): 309–20. Williams & Wilkins, 1993.Google Scholar
4 Epstein, LH. The direct effects of compliance of health outcomes. Health Psychol 1984; 3: 385–93.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.